Results 21 to 30 of about 2,835 (182)

Filgotinib in Active Noninfectious Uveitis [PDF]

JAMA Ophthalmology
ImportanceNoninfectious uveitis is a leading cause of visual impairment with an unmet need for additional treatment options.ObjectiveTo assess the efficacy and safety of filgotinib, a Janus kinase 1 (JAK1) preferential inhibitor, for the treatment of noninfectious uveitis.Design, Setting, and ParticipantsThe HUMBOLDT trial was a double-masked, placebo ...
Srivastava, Sunil K, Watkins, Timothy R, Nguyen, Quan Dong, Sharma, Sumit, Scales, David K, Dacey, Mark S, Shah, Rajiv E, Chu, David S, Grewal, Dilraj S, Faia, Lisa J, Suhler, Eric B, Genovese, Mark C, Guo, Ying, Barchuk, William T, Besuyen, Robin, Dick, Andrew D, Rosenbaum, James T   +16 more
openaire   +6 more sources

Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: analysis of the phase 2b/3 SELECTION study [PDF]

Intestinal Research
Background/Aims Obtaining and maintaining corticosteroid-free remission are important goals of treatment for ulcerative colitis (UC). Characteristics associated with achieving corticosteroid-free remission were assessed in filgotinib-treated patients in ...
Taku Kobayashi, Axel Dignass, Xavier Roblin, Yoshie Takatori, Toshihiko Kaise, Alessandra Oortwijn, Corinne Jamoul, Toshifumi Hibi   +7 more
doaj   +2 more sources

Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study [PDF]

RMD Open
Background Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs.
Hendrik Schulze-Koops, Tsutomu Takeuchi, Daniel Aletaha, Maya H Buch, Yoshiya Tanaka, Ricardo Blanco, Paul Emery, Jacques-Eric Gottenberg, Bernard G Combe, Roberto Caporali, Patrick Verschueren, Vijay Rajendran, Anna Zubrzycka-Sienkiewicz, Edmund V Ekoka Omoruyi, Francesco De Leonardis   +14 more
doaj   +2 more sources

Successful treatment of rheumatoid arthritis-associated interstitial lung disease with filgotinib: A case report on janus kinase 1 inhibition

Respirology Case Reports
Filgotinib, a janus kinase 1 (JAK1) inhibitor, is used in the treatment of rheumatoid arthritis (RA). RA‐associated interstitial lung disease (RA‐ILD) is a severe RA complication with no established effective treatment.
Takuya Inoue, Atsuhiko Sunaga
exaly   +2 more sources

Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes [PDF]

RMD Open
Objectives Long-term safety is fundamental for treatment decision-making. This integrated analysis of filgotinib clinical trials in rheumatoid arthritis (RA) and ulcerative colitis (UC) assessed adverse events of interest (AEI): major adverse ...
Zoltan Szekanecz, Yoshiya Tanaka, Laurent Peyrin-Biroulet, Stefan Schreiber, René Westhovens, Xavier Mariette, Chris Watson, C Janneke van der Woude, Hugo ten Cate, Andreas Stallmach, Christina Charles-Schoeman, Sandrine Aspeslagh, Marc Schmalzing, Margaux Faes, Sven Borchmann, Christine Rudolph, Edmund V Ekoka Omoruyi, Paul Van Hoek, Ernest HS Choy, Tomasz Masior   +19 more
doaj   +2 more sources

Filgotinib bei Colitis ulcerosa: ein Review

Journal für Gastroenterologische und Hepatologische Erkrankungen
ZusammenfassungColitis ulcerosa ist eine chronisch entzündliche Darmerkrankung mit Befall des Kolons. Die häufigsten Symptome sind blutige und schleimige Durchfälle, Stuhldrang sowie abdominelle Schmerzen. Diese Symptome stellen für die Betroffenen oft eine wesentliche gesundheitliche Beeinträchtigung dar.Filgotinib ist ein Medikament, das in oraler ...
Blesl, Andreas, Novacek, Gottfried, Reinisch, Walter, Kienbauer, Melanie, Platzer, Reingard, Wolzt, Michael, Koch, Robert, Högenauer, Christoph, Ribarics, Reiner, Moschen, Alexander   +9 more
openaire   +3 more sources

Rheumatoid Arthritis Preceded by Interstitial Lung Disease Controlled by Long‐Term Treatment With the Janus Kinase 1‐Selective Inhibitor, Filgotinib: A Case Report [PDF]

Respirology Case Reports
We present a case of active interstitial lung disease (ILD) preceding the onset of rheumatoid arthritis (RA). A 68‐year‐old man had dyspnea, decreased forced vital capacity, and elevated Krebs von den Lungen‐6 levels.
Takeo Sato, Shoko Nakazawa, Shotaro Yamamoto, Katsuya Nagatani, Kojiro Sato   +4 more
doaj   +2 more sources

Optimizing Janus kinase inhibitor therapy for ulcerative colitis: a real-world perspective [PDF]

Intestinal Research
In real-world clinical practice, 3 Janus kinase (JAK) inhibitors—tofacitinib, filgotinib, and upadacitinib—are now available for the treatment of ulcerative colitis.
Shintaro Akiyama
doaj   +2 more sources

Immune‐Mediated Thrombocytopenia in an Ulcerative Colitis Patient After Initiating Filgotinib Treatment: A Case Report [PDF]

Clinical Case Reports
Moderate‐to‐severe ulcerative colitis can be effectively treated with JAK‐1 inhibition, but platelet counts should be closely monitored, especially in active disease.
M. J. van derHoff, F. El‐Morabit, M. Löwenberg   +2 more
doaj   +2 more sources

Filgotinib: First Approval [PDF]

Drugs, 2020
Filgotinib (Jyseleca®) is an oral, ATP-competitive, reversible JAK1 preferential inhibitor that is being developed by Galapagos NV and Gilead Sciences for the treatment of inflammatory autoimmune diseases, including inflammatory arthritis and inflammatory bowel disease.
Dhillon, Sohita, Keam, Susan J.
openaire   +2 more sources